Back to Browse Journals » Vascular Health and Risk Management » Volume 8

Microencapsulated conjugated linoleic acid associated with hypocaloric diet reduces body fat in sedentary women with metabolic syndrome

Authors Carvalho RF, Uehara SK, Rosa G

Published Date December 2012 Volume 2012:8 Pages 661—667

DOI http://dx.doi.org/10.2147/VHRM.S37385

Received 27 August 2012, Accepted 9 October 2012, Published 13 December 2012

Roberta F Carvalho,1 Sofia K Uehara,2 Glorimar Rosa1,2

1Medicine Department, Federal University of Rio de Janeiro, Brazil; 2Nutrition and Dietetic Department, Josué de Castro Institute of Nutrition, Federal University of Rio de Janeiro, Brazil

Background: Animal studies have suggested beneficial effects of conjugated linoleic acid (CLA) in reducing body fat mass and improvement in the serum lipid profile and glycemia. However, these effects are controversial in humans. The purpose of this study was to investigate the effects of microencapsulated CLA supplementation on body composition, body mass index, waist circumference, and blood pressure in sedentary women with metabolic syndrome.
Methods: This study was a placebo-controlled and randomized clinical trial. Fourteen women diagnosed with metabolic syndrome received light strawberry jam enriched or not with microencapsulated CLA (3 g/day) as a mixture of 38.57% cis-9, trans-11, and 39.76% trans-10, cis-12 CLA isomers associated with a hypocaloric diet for 90 days. The subjects were monitored to assess variables associated with the metabolic syndrome, in addition to assessing adherence with the intervention.
Results: There were no significant effects of microencapsulated CLA on the lipid profile or blood pressure. Mean plasma insulin concentrations were significantly lower in women supplemented with microencapsulated CLA (Δ T90 – T0 = −12.87 ± 4.26 µU/mL, P = 0.02). Microencapsulated CLA supplementation did not alter the waist circumference, but there was a reduction in body fat mass detected after 30 days (Δ = −2.68% ± 0.82%, P = 0.02), which was maintained until the 90-day intervention period (Δ = −3.32% ± 1.41%, P = 0.02) in the microencapsulated CLA group. The placebo group showed this effect only after 90 days (Δ = −1.97% ± 0.60%, P = 0.02), but had a reduced waist circumference (Δ T90 – T0 = −4.25 ± 1.31 cm, P = 0.03).
Conclusion: Supplementation with mixed-isomer microencapsulated CLA may have a favorable effect on glycemic control and body fat mass loss at an earlier time in sedentary women with metabolic syndrome, although there were no effects on lipid profile and blood pressure.

Keywords: conjugated linoleic acid, metabolic syndrome, body composition, cardiovascular disease

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-β signaling pathway

Zhao Y, Hu JY, Li RG, Song J, Kang YJ, Liu S, Zhang DW

OncoTargets and Therapy 2015, 8:1553-1559

Published Date: 22 June 2015

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

Capolla S, Garrovo C, Zorzet S, Lorenzon A, Rampazzo E, Spretz R, Pozzato G, NΓΊΓ±ez L, Tripodo C, Macor P, Biffi S

International Journal of Nanomedicine 2015, 10:4099-4109

Published Date: 22 June 2015

Complications of the endovascular management of acute ischemic stroke

Gill HL, Siracuse JJ, Parrack IK, Huang ZS, Meltzer AJ

Vascular Health and Risk Management 2014, 10:675-681

Published Date: 28 November 2014

Aldosterone receptor antagonists: current perspectives and therapies

Guichard JL, Clark III D, Calhoun DA, Ahmed MI

Vascular Health and Risk Management 2013, 9:321-331

Published Date: 24 June 2013

Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry

Schaefer JR, Gitt AK, Sonntag F, Weizel A, Jannowitz C, Karmann B, Pittrow D, Bestehorn K

Vascular Health and Risk Management 2013, 9:71-80

Published Date: 21 February 2013

Rivaroxaban in atrial fibrillation

Giorgi MA, Miguel LS

Vascular Health and Risk Management 2012, 8:525-531

Published Date: 30 August 2012

Treatment patterns and risk factor control in patients with and without metabolic syndrome in cardiac rehabilitation

Gitt A, Jannowitz C, Karoff M, Karmann B, Horack M, Völler H

Vascular Health and Risk Management 2012, 8:265-274

Published Date: 24 April 2012

Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease

Osamu Kano, Ken Ikeda, Tetsuhito Kiyozuka, Konosuke Iwamoto, Hirono Ito, et al

Neuropsychiatric Disease and Treatment 2008, 4:707-710

Published Date: 16 February 2009